0.69
-0.0313(-4.37%)
Currency In USD
| Previous Close | 0.72 |
| Open | 0.7 |
| Day High | 0.74 |
| Day Low | 0.66 |
| 52-Week High | 2.31 |
| 52-Week Low | 0.66 |
| Volume | 1.07M |
| Average Volume | 748,011 |
| Market Cap | 86.22M |
| PE | -3.26 |
| EPS | -0.21 |
| Moving Average 50 Days | 0.84 |
| Moving Average 200 Days | 1.19 |
| Change | -0.03 |
If you invested $1000 in Atossa Therapeutics, Inc. (ATOS) 10 years ago, it would be worth $2.03 as of March 14, 2025 at a share price of $0.685. Whereas If you bought $1000 worth of Atossa Therapeutics, Inc. (ATOS) shares 5 years ago, it would be worth $867.59 as of March 14, 2025 at a share price of $0.685.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications
GlobeNewswire Inc.
Mar 11, 2025 12:15 PM GMT
SEATTLE, March 11, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, today announced its strategic d
Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care
GlobeNewswire Inc.
Feb 05, 2025 1:00 PM GMT
SEATTLE, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, extends its sincere congratulati
Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591
GlobeNewswire Inc.
Jan 30, 2025 1:17 PM GMT
SEATTLE, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, today issued the following state